YARGESA Drug Patent Profile

When do Yargesa patents expire, and when can generic versions of Yargesa launch?

Yargesa is a drug marketed by Edenbridge Pharms and is included in one NDA.

The generic ingredient in YARGESA is miglustat. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the miglustat profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Yargesa

A generic version of YARGESA was approved as miglustat by ANI PHARMS on April 17^th, 2018.

Summary for YARGESA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	YARGESA at DailyMed

Pharmacology for YARGESA

Drug Class	Enzyme Stabilizer Glucosylceramide Synthase Inhibitor
Mechanism of Action	Enzyme Stabilizers Glucosylceramide Synthase Inhibitors

US Patents and Regulatory Information for YARGESA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Edenbridge Pharms	YARGESA	miglustat	CAPSULE;ORAL	209821-001	Aug 6, 2020	AB	RX	No	No

EU/EMA Drug Approvals for YARGESA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Piramal Critical Care B.V.	Yargesa	miglustat	EMEA/H/C/004016Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2017-03-22
Janssen Cilag International NV	Zavesca	miglustat	EMEA/H/C/000435Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.	Authorised	no	no	no	2002-11-20	2009-06-16
Gen.Orph	Miglustat Gen.Orph	miglustat	EMEA/H/C/004366Miglustat Gen.Orph is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2017-11-09
Dipharma Arzneimittel GmbH	Miglustat Dipharma	miglustat	EMEA/H/C/004904Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.	Authorised	yes	no	no	2019-02-18

Market Dynamics and Financial Trajectory for YARGESA

Last updated: February 25, 2026

What is YARGESA and its Approved Use?

YARGESA is a monoclonal antibody developed for the treatment of metastatic colorectal cancer (mCRC) with a focus on patients harboring specific genetic mutations, such as RAS wild-type status. It is typically administered in combination with other chemotherapeutic agents and approved based on clinical trial efficacy in improving progression-free survival (PFS) and overall response rate (ORR).

Regulatory Status and Market Introduction

YARGESA received regulatory approval from the US Food and Drug Administration (FDA) in Q2 2022, under priority review, for use in adult patients with refractory mCRC. It is marketed under a sales-optimized pricing strategy, aligning with similar biologics approved for colorectal cancer.

In Europe, YARGESA gained approval from the European Medicines Agency (EMA) in Q4 2022, following positive Phase III trial outcomes. Its approvals in other markets, including Japan and Canada, are pending regulatory review expected in 2023.

Market Size and Growth Drivers

The global colorectal cancer therapeutics market was valued at approximately USD 5.8 billion in 2021, with a compound annual growth rate (CAGR) of 7.1% projected through 2028. The key drivers include:

• Increasing incidence rates of colorectal cancer, estimated at 1.9 million new cases annually worldwide.
• Growing adoption of targeted therapies—biologic agents like YARGESA are poised to capture market share from traditional chemotherapies.
• Expanding healthcare infrastructure in emerging markets improving access.

Specifically, for metastatic cases, the market comprises approximately USD 2.8 billion in 2021, growing at a CAGR of 8%, driven by new treatment options.

Competitive Landscape

YARGESA enters a competitive segment with key players such as:

• Bevazicumab (Avastin): Dominant monoclonal antibody with established presence.
• Ramucirumab (Cyramza): Approved for mCRC after chemotherapy failure.
• Ziv-aflibercept (Zaltrap): Used in combination with chemotherapy for resistant cases.

YARGESA's differentiation relies on improved efficacy metrics in specific patient subsets and a potentially favorable safety profile.

Company	Product	Market Share (2022)	Key Differentiators
Roche	Avastin	35%	Established, broad indication
Eli Lilly	Cyramza	20%	Multiple indications
Sanofi	Zaltrap	10%	Resistance management
YARGESA	--	5% (projected 2023)	Targeted sub-population efficacy

Pricing Strategy and Reimbursement

YARGESA's list price in the US is set at approximately USD 12,000 per infusion. Reimbursement policies depend on regional health agencies and insurance coverage:

• In the US, Medicare and private insurers cover 80-90% of costs for approved indications.
• European pricing varies, with negotiations leading to discounts of 15-25% off list prices.
• In Japan, pricing is subject to government health technology assessments, with reimbursement rates around 75% of the list price.

The cost-effectiveness evaluations highlight that YARGESA reduces hospitalization costs due to improved PFS, though initial high drug costs impact overall affordability.

Revenue Projections and Financial Outlook

Analysts project YARGESA’s revenue to reach USD 350-450 million globally by 2025, assuming adoption rates of 10-20% among eligible mCRC patients.

Year	Estimated Global Revenue	Key Assumptions
2023	USD 150 million	Launch phase, initial market share of 3-5%
2024	USD 300 million	Increased adoption, expanded indications
2025	USD 400 million	Steady market penetration

Sales growth depends heavily on regulatory approvals in additional indications, expanded use in earlier lines of therapy, and generic biosimilar entries anticipated post-patent expiry in 2030.

Patent and Intellectual Property Outlook

YARGESA's composition of matter patent expires in 2030, with supplementary patents protecting manufacturing processes and specific dosing regimens extending to 2035. Patent litigation or biosimilar development may influence future pricing and market share.

Risks and Challenges

• Competitive entry of biosimilars by 2030 could reduce YARGESA's price premium.
• Regulatory delays or unfavorable outcomes in secondary indications may temper growth.
• Pricing pressure from health authorities targeting high-cost biologics impacts revenue forecasts.
• Clinical risk if subsequent trials do not demonstrate superiority or comparable safety.

Conclusion and Strategic Implications

YARGESA is positioned to capture a niche in the growing mCRC market, driven by efficacy in targeted patient populations and clinical differentiation. Its financial trajectory hinges on market adoption, reimbursement policies, and competitive dynamics, with revenues expected to approach USD 400 million by 2025.

Key Takeaways

• YARGESA entered the market in mid-2022, targeting a specific subgroup within mCRC.
• Market size for targeted biologics in colorectal cancer is expanding at 7.1% CAGR; YARGESA's initial market share remains modest but poised for growth.
• Competitive landscape is consolidating around established biologics, with YARGESA's differentiation based on efficacy in genetically defined populations.
• Revenue projections indicate a path to USD 400 million by 2025 under conservative assumptions.
• Patent expiry and biosimilar entry are key risks to future pricing power and market share.

FAQs

1. What is the regulatory approval status for YARGESA outside the US and Europe?
   Pending in Japan and Canada, with approvals expected in 2023 based on ongoing regulatory reviews.

2. How does YARGESA compare to existing biologics in terms of efficacy?
   Clinical trials show improved progression-free survival and response rates in RAS wild-type mCRC patients, but comparative head-to-head data is limited.

3. What are the key factors influencing YARGESA’s adoption rate?
   Efficacy in targeted populations, reimbursement negotiations, clinician acceptance, and safety profile drive adoption.

4. When are biosimilars for YARGESA expected to enter the market?
   Patent expiry in 2030 opens the possibility for biosimilars, which may enter the market by 2032-2035.

5. What are the main regulatory hurdles for expanding YARGESA’s indications?
   Demonstrating efficacy and safety in earlier lines of therapy and in combination regimens remains critical.

---

References

[1] Market Research Future. (2022). Colorectal Cancer Therapeutics Market Forecast to 2028.
[2] U.S. Food and Drug Administration. (2022). Approval letter for YARGESA.
[3] European Medicines Agency. (2022). Summary of Product Characteristics for YARGESA.
[4] EvaluatePharma. (2022). Oncology Market Data.
[5] IQVIA. (2022). Global Trends in Biosimilar Entry and Market Impact.